# A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

> **NCT07466901** · NA · NOT_YET_RECRUITING · sponsor: **Jin LI** · enrollment: 30 (estimated)

## Conditions studied

- Cervical Cancer
- Radical Surgery
- Adjuvant Therapy

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** famotinib

## Key facts

- **NCT ID:** NCT07466901
- **Lead sponsor:** Jin LI
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-04-01
- **Final completion:** 2030-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466901, "A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07466901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*